Variety of eligible patients: CDEC reviewed the uncertainty in the number of clients with reasonably significant to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific professionals consulted by CADTH indicated that some sufferers who will be classified as possessing delicate or reasonable sickness may have a extreme